第二批带量采购药品招标启动 医药板块荣辱互见 石药传中标续涨5.5%
内地第二批带量采购药品招标启动,中标结果将於三天後正式发布,全国患者最快4月可用上该批药品。不过,据内媒报导,石药(01093.HK)旗下注射用紫杉醇有份中标,分析指,用於抗癌注射用紫杉醇为石药主要增长亮点,之前因市场渗透率较低,在入围集中采购後,很大机会获纳入医保名单,在医院市场销量大增下,有望抵消降价影响。
石药承昨天股价弹近半成势,今天进一步升破20天及50天线(18.25元及18.87元),最高见19.36元,创逾两个月高,现造19元,续涨5.5%,为最强蓝筹,成交增至7,305万股,涉资13.74亿元。同为蓝筹中生制药(01177.HK)反覆高见11.88元,同创逾两个月高,现造11.7元,续升3.2%,成交增至7,883万股,涉资9.11亿元。
东阳光药(01558.HK)、绿叶制药(02186.HK)及药明康德(02359.HK)也反覆升1.5%-2.9%,分别报41.9元/6.2元/1066104元,後者曾高见104.3元上市新高。
相反,威高股份(01066.HK)今早高开报10.4元创六年新高欠承接,掉头低见9.88元,现造9.94元,倒跌1.8%。石四药(02005.HK)、华润医药(03320.HK)及三生制药(01530.HK)反覆跌1%-2%,後者最弱由最高见11.54元,掉头倒跌2.1%,报11.1元,考验10天线(11.05元)。上海医药(02607.HK)高开报16.14元欠承接,未能突破昨天所创逾八个月高位,股价掉头倒跌2.7%报15.7元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.